Regorafenib治疗肝癌的临床研究进展

Regorafenib, a novel multi-kinase inhibitor, has been approved for the treatment of metastatic colorectal cancer and gastrointestinal stromal tumors. The clinical trials of Regorafenib for the treatment of hepatocellular carcinoma (HCC) are summarized. Phase Ⅰ and Ⅱ clinical trials have demonstrated the safety of Regorafenib in patients with HCC. A phase Ⅱ clinical trial has shown that as a second-line therapy for HCC, Regorafenib can achieve a relatively high disease control rate. In addition, an ongoing phase Ⅲ randomized, controlled trial will compare the safety and efficacy between Regorafenib and placebo as second-line therapies for advanced HCC. These results indicate that Regorafenib can effectively control the progression of HCC and may be used as a second-line therapy for advanced HCC